Skip to main content

Advertisement

Table 2 Demographic, serological, clinical data and medication prior to induction therapy

From: Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus

Demographic, serological, clinical data and medication MMF CYC
(number = 23) (number = 24)
SLEDAI-2 k (points); median (range) 12 (6 to 20) 14 (2 to 30)
gender female number (%) 15 (65.2) 16 (66.7)
age (years); mean ± SD 35 ± 10 34 ± 10
duration (years); median (range) 4 (1 to 24) 3 (0 to 25)
age at initial diagnosis of SLE (years); mean ± SD 29 ± 10 30 ± 10
medication   
prednisone (mg/day); median (range) 10.0 (5.0-30.0) 10.0 (0.0-250.0)
co-medication with antimalarials number (%) 15 (65.2) 11 (45.8)
preceding immunosuppressive medication number (%)   
- CYC 11 (47.8)  
- MMF   6 (25.0)
- AZA 8 (24.8) 7 (29.2)
- MTX 2 (8.7) 2 (8.3)
- CsA 1 (4.3) 1 (4.2)
- none 1 (4.3)a 8 (33.3)a
manifestations number (%)  
class III-V nephritis flare 17 (73.9) 18 (75.0)
eGFR <60 ml/min 4 (18.2) 6 (25.0)
C3c <0.9 g/L 14 (60.9)b 23 (95.8)b
neuropsychiatric 1 (4.3) 3 (12.5)
mucocutaneous/cutaneous 14 (60.9) 14 (58.3)
arthritis 8 (34.8) 6 (25.0)
serositis 2 (8.7) 5 (20.8)
myositis 2 (8.7) 3 (12.5)
autoantibodies number (%)  
anti-dsDNA >7 U/ml 21 (91.3) 21 (87.5)
anti-Ro >7 U/ml 15 (65.2) 13 (54.2)
anti-La >7 U/ml 5 (21.7) 5 (20.8)
anti-U1-RNP >5 U/ml 11 (47.8) 13 (54.2)
anti-SM >5 U/ml 8 (34.8) 11 (45.8)
  1. Statistically significant differences between patients undergoing induction therapy with CYC and MMF (Fisher’s exact test): a P = 0.0226; b P = 0.0044. AZA: azathioprine; C3c: complement factor C3c; CsA: cyclosporine A; CYC: cyclophosphamide; eGFR: estimated glomerular filtration rate; MMF: mycophenolate mofetil; MTX: methotrexate; SLE: systemic lupus erythematosus; SLEDAI-2 k: SLE disease activity index.